The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression
Authors Savvas Diafas, Douglas G Day, Jeanette A Stewart, William C Stewart
Published 15 November 2007 Volume 2007:3(5) Pages 725—732
Savvas Diafas1, Douglas G Day2, Jeanette A Stewart3, William C Stewart3,4
1Papageorgiou General Hospital, Thessaloniki, Greece; 2Omni Eye Services, Atlanta, GA, USA; 3PRN Pharmaceutical Research Network, LLC, Charleston, SC, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USA
Purpose: To evaluate progression rates with dorzolamide compared with other hypotensive agents in primary open-angle glaucoma.
Methods: Patients who were treated over 5 years with dorzolamide versus other hypotensive agents were reviewed. The groups were matched by intraocular pressure, cardiovascular history, and age.
Results: In 50 matched pairs, 2 (4%) of dorzolamide and 7 (14%) of control patients suffered glaucomatous progression (p = 0.09). Progressed dorzolamide patients had pressures of 13 versus 15–20 mmHg in the control group. Control patients progressed after 26.4 months and dorzolamide patients after 38.9 months.
Conclusions: Although the results were not statistically significant, this pilot trial demonstrated a trend towards less glaucomatous progression in patients treated with an assumed active blood flow product. In addition, progression was delayed and occurred at lower pressures in the active blood flow group. This pilot trial suggests that future prospective, long-term, clinical outcomes studies in patients treated with a medicine with a positive ocular blood flow effect may be warranted.
Keywords: blood flow, ocular hypotensive agents, dorzolamide, glaucomatous progression